Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:AXSM NASDAQ:IDYA NASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$123.80-0.7%$116.69$5.59▼$148.83$9.81B0.841.11 million shs438,505 shsAXSMAxsome Therapeutics$218.28-0.9%$173.69$96.09▼$234.29$11.23B0.59701,622 shs162,879 shsIDYAIDEAYA Biosciences$28.230.0%$32.00$16.84▼$39.28$2.48B-0.041.10 million shs133,282 shsPRAXPraxis Precision Medicines$334.54+0.4%$317.78$35.21▼$356.00$9.30B2.76457,872 shs114,690 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-1.49%+6.19%+7.01%+5.93%+1,766.02%AXSMAxsome Therapeutics-1.26%+5.81%+30.27%+20.42%+98.29%IDYAIDEAYA Biosciences-1.74%-2.96%-8.64%-12.22%+58.38%PRAXPraxis Precision Medicines-1.42%+4.53%+8.67%+4.29%+774.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$123.80-0.7%$116.69$5.59▼$148.83$9.81B0.841.11 million shs438,505 shsAXSMAxsome Therapeutics$218.28-0.9%$173.69$96.09▼$234.29$11.23B0.59701,622 shs162,879 shsIDYAIDEAYA Biosciences$28.230.0%$32.00$16.84▼$39.28$2.48B-0.041.10 million shs133,282 shsPRAXPraxis Precision Medicines$334.54+0.4%$317.78$35.21▼$356.00$9.30B2.76457,872 shs114,690 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-1.49%+6.19%+7.01%+5.93%+1,766.02%AXSMAxsome Therapeutics-1.26%+5.81%+30.27%+20.42%+98.29%IDYAIDEAYA Biosciences-1.74%-2.96%-8.64%-12.22%+58.38%PRAXPraxis Precision Medicines-1.42%+4.53%+8.67%+4.29%+774.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.93Moderate Buy$137.1510.79% UpsideAXSMAxsome Therapeutics 2.90Moderate Buy$251.2615.11% UpsideIDYAIDEAYA Biosciences 2.82Moderate Buy$50.6979.58% UpsidePRAXPraxis Precision Medicines 3.00Buy$591.8376.91% UpsideCurrent Analyst Ratings BreakdownLatest IDYA, AXSM, PRAX, and ABVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$420.005/8/2026PRAXPraxis Precision Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$130.00 ➝ $166.005/8/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.005/7/2026PRAXPraxis Precision Medicines Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/7/2026IDYAIDEAYA Biosciences MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$52.00 ➝ $50.005/5/2026AXSMAxsome Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$280.005/5/2026AXSMAxsome Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$225.00 ➝ $255.005/5/2026AXSMAxsome Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$242.00 ➝ $302.005/5/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$270.00 ➝ $290.005/5/2026AXSMAxsome Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$217.00 ➝ $242.005/5/2026AXSMAxsome Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$225.00 ➝ $255.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/AAXSMAxsome Therapeutics$708.24M15.86N/AN/A$1.06 per share205.92IDYAIDEAYA Biosciences$225.27M11.01N/AN/A$10.67 per share2.65PRAXPraxis Precision Medicines$8.55M1,090.47N/AN/A$34.85 per share9.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.37N/AN/AN/AN/A-146.43%-88.69%5/25/2026 (Estimated)AXSMAxsome Therapeutics-$183.17M-$3.73N/A54.16N/A-26.59%-267.16%-28.53%N/AIDYAIDEAYA Biosciences-$113.70M-$1.60N/AN/AN/AN/A-14.24%-13.09%N/APRAXPraxis Precision Medicines-$303.27M-$13.46N/AN/AN/AN/A-58.74%-53.54%N/ALatest IDYA, AXSM, PRAX, and ABVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/25/2026Q1 2026ABVXAbivax-$0.9359N/AN/AN/A$0.40 millionN/A5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/5/2026Q1 2026IDYAIDEAYA Biosciences-$1.07-$1.11-$0.04-$1.11$5.04 million$6.56 million5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million3/23/2026Q4 2025ABVXAbivax-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 million2/23/2026Q4 2025AXSMAxsome Therapeutics-$0.70-$0.56+$0.14-$0.56$191.33 million$196.00 million2/19/2026Q4 2025PRAXPraxis Precision Medicines-$3.00-$3.50-$0.50-$3.50$0.26 millionN/A2/17/2026Q4 2025IDYAIDEAYA Biosciences-$1.03-$0.94+$0.09-$0.94$5.95 million$10.88 million2/14/2026Q4 2025ABVXAbivaxN/A-$1.20N/A-$1.20N/A$0.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.758.75AXSMAxsome Therapeutics2.271.391.48IDYAIDEAYA BiosciencesN/A10.7411.34PRAXPraxis Precision MedicinesN/A10.2210.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%AXSMAxsome Therapeutics81.49%IDYAIDEAYA Biosciences98.29%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AAXSMAxsome Therapeutics20.60%IDYAIDEAYA Biosciences2.50%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.29 millionN/ANot OptionableAXSMAxsome Therapeutics38051.46 million40.86 millionOptionableIDYAIDEAYA Biosciences8087.86 million85.66 millionOptionablePRAXPraxis Precision Medicines11027.87 million27.12 millionOptionableIDYA, AXSM, PRAX, and ABVX HeadlinesRecent News About These CompaniesPraxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $166.002 hours ago | marketbeat.comBTIG Research Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)3 hours ago | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Issues Earnings ResultsMay 7 at 7:52 PM | marketbeat.comPraxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7 at 3:37 PM | finanznachrichten.dePraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7 at 8:00 AM | globenewswire.comStrs Ohio Invests $943,000 in Praxis Precision Medicines, Inc. $PRAXMay 7 at 5:44 AM | marketbeat.comPraxis earnings up next as biotech nears commercial transformationMay 6 at 11:40 PM | investing.comPraxis Precision Medicines, Inc. $PRAX Shares Bought by Vanguard Group Inc.May 6 at 8:14 AM | marketbeat.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 5 at 4:01 PM | globenewswire.comPraxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor ConferenceMay 4, 2026 | globenewswire.comPraxis (PRAX) Aligns Pay With Ulixacaltamide Progress Is Incentive Design Now a Key Edge?May 3, 2026 | finance.yahoo.comA Look At Praxis Precision Medicines (PRAX) Valuation After Strong Long Term Shareholder ReturnsMay 3, 2026 | finance.yahoo.comOptimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for UlixacaltamideApril 29, 2026 | finance.yahoo.comMoody Aldrich Partners LLC Buys New Position in Praxis Precision Medicines, Inc. $PRAXApril 29, 2026 | marketbeat.comPictet Asset Management Holding SA Makes New $71.09 Million Investment in Praxis Precision Medicines, Inc. $PRAXApril 29, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Moderna (MRNA)April 27, 2026 | theglobeandmail.comPraxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in NeurologyApril 27, 2026 | insidermonkey.comM&T Bank Corp Purchases Shares of 12,586 Praxis Precision Medicines, Inc. $PRAXApril 27, 2026 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Takes Position in Praxis Precision Medicines, Inc. $PRAXApril 27, 2026 | marketbeat.comPraxis Precision Medicines (PRAX) Gets a Buy from LifeSci CapitalApril 24, 2026 | theglobeandmail.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Buy" by BrokeragesApril 24, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIDYA, AXSM, PRAX, and ABVX Company DescriptionsAbivax NASDAQ:ABVX$123.80 -0.85 (-0.68%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Axsome Therapeutics NASDAQ:AXSM$218.28 -1.95 (-0.88%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.IDEAYA Biosciences NASDAQ:IDYA$28.23 -0.01 (-0.05%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Praxis Precision Medicines NASDAQ:PRAX$334.54 +1.26 (+0.38%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
